X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will used to advance the clinical development of Aileron’s lead product candidate, LTI-03. Currently, it is being evaluated in an early-stage clinical trial for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2024
Details:
The net proceeds will be used to advance the development of LTI-03, a peptide representing an important region of the Caveolin 1 (Cav1) protein, for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 01, 2024
Details:
LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells. It is being developed for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
The acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF).
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Aileron Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
Aileron intends to use the proceeds primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Clear Street LLC
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
